Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study

This is a prospective, open-label, proof-of-concept study of tofacitinib, a Janus kinase inhibitor, as a steroid sparing therapy in corticosteroid-dependent pulmonary sarcoidosis. 5 patients with corticosteroid-dependent pulmonary sarcoidosis were treated with tofacitinib 5 mg twice daily. The prima...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lung
Hlavní autoři: Friedman, Marcia A., Le, Brian, Stevens, Janelle, Desmarais, Julianna, Seifer, Daniel, Ogle, Kimberly, Choi, Dongseok, Harrington, Christina A., Jackson, Peter, Rosenbaum, James T.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092019/
https://ncbi.nlm.nih.gov/pubmed/33825964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00408-021-00436-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky